Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Aug 18;28(Suppl 1):28–37. doi: 10.1002/clc.4960281306

Practical algorithms for pharmacologic management of the post myocardial infarction patient

James A Reiffel 1,✉
PMCID: PMC6654480  PMID: 16450810

Abstract

The pharmacologic management of the patient post myocardial infarction (MI) aims to achieve several goals. Chief among these is to prevent subsequent events, which include death, reinfarction, and rehospitalization. Secondary goals include preventing arrhythmias, minimizing left ventricular (LV) remodeling, and preventing progression to heart failure. This review describes practical algorithms for use in the pharmacologic management of the patient post MI based on American Heart Association/American College of Cardiology guidelines. The intensity of drug treatment is determined guided by the degree of LV dysfunction and the presence or absence of ischemia and arrhythmic risk markers. All patients post MI require an angiotensin‐converting enzyme (ACE) inhibitor and antiplatelet therapy, usually with aspirin. In individuals who cannot tolerate an ACE inhibitor, an angiotensin receptor blocker (ARB) is an adequate substitute. Numerous studies document the efficacy of ACE inhibitors, which decrease mortality and the risk of heart failure and stroke. Aldosterone blockade is recommended long‐term for patients post MI with an LV ejection fraction ≤ 40% and either symptomatic heart failure or diabetes. Use of a beta blocker is an important addition to most post‐MI drug regimens. Beta blockers decrease mortality and are especially effective in patients with impaired LV function. Among the beta blockers, carvedilol, which also has alpha‐adrenergic receptor blocking activity, was found to decrease mortality significantly in patients with low ejection fractions and heart failure. Another drug therapy of value in post‐MI treatment is use of calcium‐channel blockers. These are restricted to patients with conserved LV function in whom congestion is absent and in whom beta blockers are contraindicated. Current guidelines also recommend that patients post MI with elevated cholesterol levels should be prescribed lipid therapy with a statin at hospital discharge.

Keywords: angiotensin‐converting enzyme inhibitor, beta blocker, angiotensin receptor blocker, calcium‐channel blocker

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

References

  • 1. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK: ACC/AHA guidelines for the management of patients with ST‐elevation myocardial infarction—executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588–636 [DOI] [PubMed] [Google Scholar]
  • 2. Yusuf S, Wittes J, Friedman L: Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. J Am Med Assoc 1988; 260: 2088–2093 [PubMed] [Google Scholar]
  • 3. CAPRIE Steering Committee : A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329–1339 [DOI] [PubMed] [Google Scholar]
  • 4. Randomised double‐blind trial of fixed low‐dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Lancet 1997; 350: 389–396 [PubMed] [Google Scholar]
  • 5. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669–677 [DOI] [PubMed] [Google Scholar]
  • 6. Kober L, Torp‐Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC: A clinical trial of the angiotensin‐converting‐enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670–1676 [DOI] [PubMed] [Google Scholar]
  • 7. AIRE Study Investigators : Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342: 821–828 [PubMed] [Google Scholar]
  • 8. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Study Investigators (published errata appear in N Engl J Med 2000; 342: 748 and [DOI] [PubMed] [Google Scholar]; N Engl J Med 2000; 342: 1376). [Google Scholar]; N Engl J Med 2000; 342: 145–153 10639539 [Google Scholar]
  • 9. Fox KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double‐blind, placebo‐controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–788 [DOI] [PubMed] [Google Scholar]
  • 10. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL: Angiotensin‐converting‐enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058–2068 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Bigger JT Jr: Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary‐artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997; 337: 1569–1575 [DOI] [PubMed] [Google Scholar]
  • 12. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335: 1933–1940 [DOI] [PubMed] [Google Scholar]
  • 13. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877–883 [DOI] [PubMed] [Google Scholar]
  • 14. Wienbergen H, Schiele R, Gitt AK, Juenger C, Heer T, Meisenzahl C, Landgraf H, Bossaller C, Senges J: Impact of ramipril versus other angiotensin‐converting enzyme inhibitors on outcome of unselected patients with ST‐elevation acute myocardial infarction. Am J Cardiol 2002; 90: 1045–1049 [DOI] [PubMed] [Google Scholar]
  • 15. Kober L, Torp‐Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC: A clinical trial of the angiotensin‐converting‐enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670–1676 [DOI] [PubMed] [Google Scholar]
  • 16. Torp‐Pedersen C, Kober L, Carlsen J: Angiotensin‐converting enzyme inhibition after myocardial infarction: The Trandolapril Cardiac Evaluation Study. Am Heart J 1996; 132: 235–243 [DOI] [PubMed] [Google Scholar]
  • 17. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–1906 [DOI] [PubMed] [Google Scholar]
  • 18. Dickstein K, Kjekshus J: Effects of losartan and captopril on mortality and morbidity in high‐ risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752–760 [DOI] [PubMed] [Google Scholar]
  • 19. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM‐Overall programme. Lancet 2003; 362: 759–766 [DOI] [PubMed] [Google Scholar]
  • 20. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA: Effects of candesartan in patients with chronic heart failure and reduced left‐ventricular systolic function taking angiotensin‐converting‐enzyme inhibitors: The CHARM‐Added trial. Lancet 2003; 362: 767–771 [DOI] [PubMed] [Google Scholar]
  • 21. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K: Effects of candesartan in patients with chronic heart failure and reduced left‐ventricular systolic function intolerant to angiotensin‐converting‐enzyme inhibitors: The CHARM‐Alternative trial. Lancet 2003; 362: 772–776 [DOI] [PubMed] [Google Scholar]
  • 22. Brown NJ, Kumar S, Painter CA, Vaughan DE: ACE inhibition versus angiotensin type 1 receptor antagonism: Differential effects on PAI‐1 over time. Hypertension 2002; 40: 859–865 [DOI] [PubMed] [Google Scholar]
  • 23. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321 [DOI] [PubMed] [Google Scholar]
  • 24. Pedersen TR: Six‐year follow‐up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. N Engl J Med 1985; 313: 1055–1058 [DOI] [PubMed] [Google Scholar]
  • 25. Beta‐Blocker Heart Attack Trial Research Group : A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. J Am Med Assoc 1982; 247: 1707–1714 [DOI] [PubMed] [Google Scholar]
  • 26. Chadda K, Goldstein S, Byington R, Curb JD: Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986; 73: 503–510 [DOI] [PubMed] [Google Scholar]
  • 27. Houghton T, Freemantle N, Cleland JG: Are beta‐blockers effective in patients who develop heart failure soon after myocardial infarction? A meta‐regression analysis of randomised trials. Eur J Heart Fail 2000; 2: 333–340 [DOI] [PubMed] [Google Scholar]
  • 28. Viscoli CM, Horwitz RI, Singer BH: Beta‐blockers after myocardial infarction: Influence of first‐year clinical course on long‐term effectiveness. Ann Intern Med 1993; 118: 99–105 [DOI] [PubMed] [Google Scholar]
  • 29. CAPRICORN Investigators : Effect of carvedilol on outcome after myocardial infarction in patients with left‐ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001; 357: 1385–1390 [DOI] [PubMed] [Google Scholar]
  • 30. McMurray JJ, Dargie HJ, Ford I: Carvedilol reduces supraventricular and ventricular arrhythmias after myocardial infarction: Evidence from the CAPRICORN study (abstr 3303). Circulation 2001; 104: II–700 [Google Scholar]
  • 31. Doughty RN, Whalley GA, Walsh HA, Gamble GD, Lopez‐Sendon J, Sharpe N: Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: The CAPRICORN Echo Substudy. Circulation 2004; 109: 201–206 [DOI] [PubMed] [Google Scholar]
  • 32. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR: Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996; 17 (suppl B): 8–16 [DOI] [PubMed] [Google Scholar]
  • 33. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR: Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94: 2817–2825 [DOI] [PubMed] [Google Scholar]
  • 34. Poole‐Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp‐Pedersen C, Scherhag A, Skene A: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003; 362: 7–13 [DOI] [PubMed] [Google Scholar]
  • 35. Dornhorst A, Powell SH, Pensky J: Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. Lancet 1985; 1: 123–126 [DOI] [PubMed] [Google Scholar]
  • 36. Holzgreve H, Nakov R, Beck K, Janka HU: Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens 2003; 16: 381–386 [DOI] [PubMed] [Google Scholar]
  • 37. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS: Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. J Am Med Assoc 2004; 292: 2227–2236 [DOI] [PubMed] [Google Scholar]
  • 38. Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B, Arnold JM, Moyé L, Pfeffer M: Additive beneficial effects of beta‐blockers to angiotensin‐converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol 1997; 29: 229–236 [DOI] [PubMed] [Google Scholar]
  • 39. McMurray JJ: Major beta blocker mortality trials in chronic heart failure: A critical review. Heart 1999; 82 (suppl 4): IV14–IV22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. ISIS‐1 Collaborative Group : Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS‐1. First International Study of Infarct Survival Collaborative Group. Lancet 1986; 2: 57–66 [PubMed] [Google Scholar]
  • 41. MIAMI Trial Research Group : Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo‐controlled international trial. The MIAMI Trial Research Group. Eur Heart J 1985; 6: 199–226 [PubMed] [Google Scholar]
  • 42. Second Chinese Cardiac Study (CCS‐2) Collaborative Group : Rationale, design and organization of the Second Chinese Cardiac Study (CCS‐2): A randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. J Cardiovasc Risk 2000; 7: 435–441 [PubMed] [Google Scholar]
  • 43. Collins R: COMMITT/CCS‐2 (Clopidogrel & Metoprolol in Myocardial Infarction Trial/Second Chinese Cardiac Study 2005). Clin Cardiol 2005; 28: 303–308 [Google Scholar]
  • 44. The Multicenter Diltiazem Postinfarction Trial Research Group : The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385–392 [DOI] [PubMed] [Google Scholar]
  • 45. Hansen JF, Hagerup L, Sigurd B, Pedersen F, Mellemgaard K, Pedersen‐Bjergaard O, Mortensen LS: Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Danish Verapamil Infarction Trial (DAVIT) Study Group. Am J Cardiol 1997; 79: 738–741 [DOI] [PubMed] [Google Scholar]
  • 46. Hansen JF: Secondary prevention with calcium antagonists after acute myocardial infarction. Drugs 1992; 44 (suppl 1): 33–43 [DOI] [PubMed] [Google Scholar]
  • 47. Rouleau JL, Talajic M, Sussex B, Potvin L, Warnica W, Davies RF, Gardner M, Stewart D, Plante S, Dupuis R, Lauzon C, Ferguson J, Mikes E, Balnozan V, Savard P: Myocardial infarction patients in the 1990s—their risk factors, stratification and survival in Canada: The Canadian Assessment of Myocardial Infarction (CAMI) Study. J Am Coll Cardiol 1996; 27: 1119–1127 [DOI] [PubMed] [Google Scholar]
  • 48. Pepine CJ, Handberg EM, Cooper‐DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia‐Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW: A calcium antagonist vs. a non‐calcium antagonist hypertension treatment strategy for patients with coronary artery disease: The International Verapamil‐Trandolapril Study (INVEST): A randomized controlled trial. J Am Med Assoc 2003; 290: 2805–2816 [DOI] [PubMed] [Google Scholar]
  • 49. Pahor M, Guralnik JM, Corti MC, Foley DJ, Carbonin P, Havlik RJ: Long‐term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1191–1197 [DOI] [PubMed] [Google Scholar]
  • 50. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. J Am Med Assoc 2001; 285: 1711–1718 [DOI] [PubMed] [Google Scholar]
  • 51. Bickel C, Rupprecht HJ, Blankenberg S, Espinola‐Klein C, Rippin G, Hafner G, Lotz J, Prellwitz W, Meyer J: Influence of HMG‐CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol 2002; 82: 25–31 [DOI] [PubMed] [Google Scholar]
  • 52. Balk EM, Lau J, Goudas LC, Jordan HS, Kupelnick B, Kim LU, Karas RH: Effects of statins on nonlipid serum markers associated with cardiovascular disease: A systematic review. Ann Intern Med 2003; 139: 670–682 [DOI] [PubMed] [Google Scholar]
  • 53. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E: Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. J Am Med Assoc 2004; 292: 1307–1316 [DOI] [PubMed] [Google Scholar]
  • 54. Ferrieres J, Cambou JP, Gueret P, Boutalbi Y, Lablanche JM, Hanania G, Genes N, Cantet C, Danchin N: Effect of early initiation of statins on survival in patients with acute myocardial infarction (the USIC 2000 Registry). Am J Cardiol 2005; 95: 486–489 [DOI] [PubMed] [Google Scholar]
  • 55. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico : Dietary supplementation with n‐3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI‐Prevenzione trial. Lancet 1999; 354: 447–455 [PubMed] [Google Scholar]
  • 56. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F: Early protection against sudden death by n‐3 polyunsaturated fatty acids after myocardial infarction: Time‐course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)‐Prevenzione. Circulation 2002; 105: 1897–1903 [DOI] [PubMed] [Google Scholar]
  • 57. Arntz HR: Recommendations for secondary prevention after myocardial infarction. Z. Kardiol 2004; 93 (suppl 1): I23–I25 [DOI] [PubMed] [Google Scholar]
  • 58. The SOLVD Investigators : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302 [DOI] [PubMed] [Google Scholar]
  • 59. MERIT‐HF Investigators : Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‐HF). Lancet 1999; 353: 2001–2007 [PubMed] [Google Scholar]
  • 60. CIBIS‐II Investigators : The Cardiac Insufficiency Bisoprolol Study II (CIBIS‐II): A randomised trial. Lancet 1999; 353: 9–13 [PubMed] [Google Scholar]
  • 61. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717 [DOI] [PubMed] [Google Scholar]
  • 62. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651–1658 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES